Last updated: September 8, 2026
Revumenib citrate, marketed in the United States as Revuforj, is Syndax Pharmaceuticals’ first commercial product and the first FDA-approved menin inhibitor. The FDA approved Revuforj on November 15, 2024, for adults and children with relapsed or refractory acute leukemia with a lysine methyltransferase 2A, or KMT2A, translocation.[1] The approval created a targeted market in a genetically defined leukemia population rather than a broad acute myeloid leukemia franchise.
Revumenib’s commercial trajectory depends on four factors: rapid adoption in molecularly selected relapsed disease, expansion into earlier treatment lines, durability of response, and the ability to defend pricing and market share against competing menin inhibitors. Syndax entered launch with no established commercial revenue base, making Revuforj the company’s central financial asset.
What is revumenib citrate and what is Revuforj approved to treat?
Revumenib is an oral, small-molecule inhibitor of the menin-KMT2A interaction. The drug is designed to suppress abnormal transcriptional programs associated with KMT2A-rearranged leukemia and certain NPM1-mutated leukemias.
The FDA-approved indication covers:
- Adults with relapsed or refractory acute leukemia with a KMT2A translocation.
- Pediatric patients aged 1 year and older with relapsed or refractory acute leukemia with a KMT2A translocation.
- Patients with KMT2A-rearranged acute myeloid leukemia, acute lymphoblastic leukemia, and mixed-phenotype acute leukemia.
The initial approval was granted through the FDA accelerated approval pathway. The regulatory endpoint was overall response rate and duration of response in the AUGMENT-101 study.[1]
Revuforj dosage forms and administration
Revuforj is supplied as oral tablets in 110 mg and 160 mg strengths. The recommended adult dosing is generally 270 mg once daily during a 28-day cycle, subject to dose modification and drug-interaction management.[2]
The label includes important restrictions involving:
- QTc prolongation.
- Differentiation syndrome.
- Strong or moderate CYP3A4 inhibitors and inducers.
- Embryo-fetal toxicity.
- Hepatotoxicity and laboratory monitoring.
These safety requirements can increase monitoring costs and may influence prescribing in community oncology settings.
How effective is revumenib in relapsed or refractory KMT2A-rearranged leukemia?
Revumenib received approval based on results from AUGMENT-101. In the FDA-reviewed population, the drug produced a clinically meaningful response rate in heavily pretreated patients with KMT2A-translocated acute leukemia.[1]
| Clinical measure |
Revumenib result |
| Overall response rate |
Approximately 22.8% |
| Complete remission or complete remission with partial hematologic recovery |
Approximately 22% |
| Median duration of response |
Approximately 6 months |
| Regulatory basis |
Accelerated approval |
| Study |
AUGMENT-101 |
| Target population |
Relapsed or refractory KMT2A-translocated acute leukemia |
Responses are commercially important because the treatment population has limited options, high mortality, and frequent need for bridging therapy to allogeneic stem-cell transplantation. Revumenib may be used to achieve remission before transplant, which can support demand even when treatment duration is relatively short.
The main limitation is the narrow addressable population. Revumenib is not approved for unselected AML, and its commercial potential is therefore tied to molecular testing and the prevalence of KMT2A rearrangements.
How large is the revumenib citrate market?
The initial Revuforj market is a rare-disease hematology market. KMT2A rearrangements occur in a minority of acute leukemias, with a higher frequency in infant and pediatric acute lymphoblastic leukemia and a smaller but important share of adult AML and ALL.[3]
The addressable population has three layers:
- Patients with KMT2A-rearranged acute leukemia.
- Patients whose disease has relapsed or become refractory.
- Patients who remain medically eligible for oral targeted treatment.
The commercial population is likely to expand if revumenib moves into first-line or maintenance treatment. Syndax has pursued clinical development in newly diagnosed disease and in NPM1-mutated AML, a larger molecular segment than KMT2A-rearranged leukemia.[4]
Market drivers
Revumenib demand is supported by:
- High unmet need after relapse.
- Limited targeted therapies for KMT2A-rearranged leukemia.
- Oral administration.
- Potential use as a bridge to transplant.
- Increasing use of next-generation sequencing and molecular classification.
- Potential expansion into NPM1-mutated AML.
- Potential combination use with chemotherapy, venetoclax, hypomethylating agents, or other targeted therapies.
Market constraints
The principal commercial constraints are:
- Small initial patient population.
- Short treatment duration for patients proceeding to transplantation or experiencing progression.
- Serious adverse-event monitoring.
- Dependence on specialist hematology centers.
- Competing investigational menin inhibitors.
- The need for confirmatory trials after accelerated approval.
- Reimbursement complexity for a rare molecular subtype.
What is the financial trajectory for Syndax and Revuforj?
Revuforj is Syndax’s first marketed drug and changes the company’s financial profile from development-stage biotechnology to commercial oncology.
Before approval, Syndax’s financial results were primarily driven by research expenses, clinical development, licensing income, collaboration payments, and cash raised through equity or debt financing. Following approval, the key financial variables became:
- Net product sales.
- Gross-to-net deductions.
- Commercial infrastructure costs.
- Medical-affairs and field-force expenses.
- Manufacturing costs.
- Postmarketing and confirmatory-trial spending.
- Cash runway relative to launch investment.
A narrow rare-leukemia launch can produce meaningful revenue per patient but may not immediately generate positive operating income. Initial expenses are likely to remain elevated because Syndax must establish diagnostic outreach, reimbursement support, distribution, pharmacovigilance, and specialist sales coverage.
Revenue model
Revuforj revenue is driven by patient starts, treatment duration, and net price. A simplified commercial model is:
| Variable |
Commercial effect |
| Molecular testing rate |
Determines how many eligible patients are identified |
| KMT2A relapse incidence |
Sets the core patient pool |
| Treatment initiation rate |
Converts diagnosis into prescriptions |
| Duration of response |
Increases revenue per patient |
| Transplant conversion |
May shorten treatment duration but supports use as bridge therapy |
| Net price after rebates |
Determines realized revenue |
| NPM1 expansion |
Could materially enlarge the market |
| Combination regimens |
Could increase duration and treatment penetration |
Revumenib’s first indication is unlikely to support a large-cap oncology revenue profile on its own. The financial upside is more dependent on label expansion, especially into NPM1-mutated AML, than on the initial KMT2A population alone.
When does revumenib lose market exclusivity?
Revumenib’s commercial exclusivity will be determined by several overlapping protections:
- Patent protection covering the compound and related menin-inhibitor chemistry.
- Formulation and dosage patents.
- Method-of-use patents covering KMT2A-rearranged leukemia and other hematologic malignancies.
- FDA orphan-drug exclusivity.
- FDA five-year new chemical entity exclusivity.
- Pediatric exclusivity, if granted.
- Regulatory exclusivity attached to the accelerated approval and label.
The FDA approved Revuforj as a new molecular entity. The product therefore received five years of U.S. new chemical entity exclusivity, subject to statutory exceptions for certain patent challenges.[5] The product also qualifies for orphan-drug exclusivity for the approved rare disease indication. Orphan exclusivity generally prevents FDA approval of the same drug for the same disease or condition for seven years, although it does not block all competing products or all uses.[6]
The exact generic-entry date depends on Orange Book-listed patents, patent-term adjustment, patent-term extension, pediatric exclusivity, and any Paragraph IV litigation or settlement.
Revuforj exclusivity framework
| Protection |
Likely commercial role |
| New chemical entity exclusivity |
Blocks certain abbreviated approvals for five years |
| Orphan-drug exclusivity |
Protects the same drug and indication for seven years |
| Composition-of-matter patent |
Primary barrier to generic chemical entry |
| Method-of-use patents |
Can restrict labeled use or induce litigation |
| Formulation patents |
May protect specific dosage forms or release profiles |
| Pediatric exclusivity |
Can add six months if awarded |
| Patent-term extension |
May extend one qualifying patent by up to five years, subject to limits |
Publicly available regulatory and corporate materials do not establish a single reliable final loss-of-exclusivity date for every Revuforj use. Any analysis based only on the FDA approval date would understate the importance of patent-term calculations and Orange Book listings.
What patents protect revumenib citrate?
The relevant Revumenib patent estate is expected to include compound, pharmaceutical composition, therapeutic-use, and treatment-regimen claims. Syndax has described intellectual-property protection for revumenib and its use in genetically defined leukemias in corporate securities filings and investor materials.[7]
The highest-value patent categories are:
Composition-of-matter patents
These patents protect revumenib or closely defined chemical structures. They are generally the strongest barrier against conventional generic substitution because a generic manufacturer must avoid the claimed molecule or successfully challenge the patent.
Formulation and dosage patents
These patents may cover:
- Oral tablets.
- Specific dosage strengths.
- Pharmaceutical compositions.
- Treatment schedules.
- Dose escalation or dose modification.
- Combinations with CYP3A4-modifying medicines.
- Pediatric administration.
Formulation patents are weaker than composition patents if the active molecule can be marketed through a non-infringing formulation. Their value increases when they cover the commercially dominant tablet, dose, or administration schedule.
Method-of-use patents
Method patents may cover treatment of:
- KMT2A-rearranged leukemia.
- NPM1-mutated AML.
- Relapsed or refractory disease.
- Combination treatment with standard AML regimens.
- Use as a bridge to hematopoietic stem-cell transplantation.
Method-of-use patents can support litigation against a generic filing a Paragraph IV certification, but their practical protection depends on claim scope, labeling, physician prescribing behavior, and the availability of non-infringing uses.
What is the Orange Book status of Revuforj?
Revuforj is an FDA-approved small molecule rather than a biologic, so its relevant listing framework is the FDA Orange Book rather than the Purple Book. Orange Book-listed patents may include patents covering the active ingredient, drug product, or approved method of use.[5]
A Paragraph IV applicant could challenge an Orange Book-listed patent by asserting that the patent is invalid, unenforceable, or not infringed. The filing of a qualifying Paragraph IV notice can trigger patent litigation and, if litigation is filed within the statutory period, a 30-month stay of FDA approval.
The key Orange Book questions for Revuforj are:
- Which patents are listed?
- Which claims cover the approved tablet strengths?
- Which listed patents expire first?
- Are any patents eligible for pediatric exclusivity?
- Has any applicant submitted an abbreviated new drug application?
- Has Syndax filed patent litigation?
- Has any settlement created an authorized generic or delayed-entry date?
No established generic competition or public Revuforj Paragraph IV launch was identified in the core approval-era record.
Which companies are challenging revumenib?
No approved generic competitor was present at the time of the initial launch. Competitive pressure is more likely to come first from other menin inhibitors than from conventional generics.
Menin-inhibitor competitors
| Company |
Product |
Development focus |
Competitive position |
| Kura Oncology |
Ziftomenib, KO-539 |
NPM1-mutated AML and KMT2A-rearranged AML |
Most direct clinical competitor |
| Johnson & Johnson |
JNJ-75276617 |
Menin-inhibitor development |
Potential large-company entrant |
| Other biotechnology companies |
Earlier-stage menin inhibitors |
Genetically defined AML and ALL |
Longer-term pipeline risk |
Ziftomenib has been evaluated in relapsed or refractory AML, particularly NPM1-mutated disease. The competitive comparison will depend on response durability, differentiation syndrome, QT effects, dosing convenience, combination data, and the breadth of eventual labels.
How does revumenib compare with ziftomenib?
Revumenib has the lead in regulatory status because it became the first approved menin inhibitor. Ziftomenib has strategic importance because NPM1-mutated AML may represent a larger commercial market than KMT2A-rearranged leukemia.
| Factor |
Revumenib |
Ziftomenib |
| Developer |
Syndax Pharmaceuticals |
Kura Oncology |
| Mechanism |
Menin inhibition |
Menin inhibition |
| First approval |
Yes, Revuforj in 2024 |
No approval at initial Revuforj launch |
| Initial approved population |
Relapsed/refractory KMT2A-translocated acute leukemia |
Clinical development focused on NPM1-mutated AML |
| Commercial advantage |
First-mover status and approved label |
Potentially larger NPM1 market |
| Key risk |
Narrow initial population and safety monitoring |
Regulatory execution and differentiation from Revuforj |
| Market expansion |
NPM1-mutated AML and earlier lines |
KMT2A and broader combination use |
Revumenib’s first-mover advantage may translate into molecular testing relationships, physician familiarity, treatment guidelines, and real-world evidence. That advantage could weaken if a competitor delivers better response durability, lower toxicity, simpler dosing, or broader combination utility.
What generic entry risks exist for revumenib?
Generic entry risk is low during the initial regulatory and patent-protected period but increases after composition patents and regulatory exclusivities expire.
The most credible entry scenarios are:
- A Paragraph IV challenge to composition-of-matter patents.
- A challenge to formulation or dosage patents.
- A generic label carve-out directed to unprotected indications.
- An authorized generic arrangement.
- A competing branded menin inhibitor obtaining a broader label before generic entry.
- A 505(b)(2) product using a different formulation or administration approach.
For a rare oncology drug, generic entry may be commercially less aggressive than for a high-volume primary-care product. Manufacturing economics, limited patient volume, specialty distribution, and the need for oncology-support infrastructure can reduce the attractiveness of immediate commodity competition.
What manufacturing and supply-chain barriers affect revumenib?
Revumenib is an oral small molecule, so it does not have the manufacturing complexity of a monoclonal antibody or cell therapy. The main barriers are chemical-process control, tablet production, quality testing, and reliable supply of active pharmaceutical ingredient.
Commercial risks include:
- Scale-up from clinical to commercial manufacturing.
- Dependence on qualified contract manufacturers.
- Control of impurities and polymorphic form.
- Stability of the drug product.
- Supply continuity for two tablet strengths.
- Pediatric and adult dose flexibility.
- Management of controlled distribution and specialty-pharmacy channels.
Manufacturing patents can add protection if they cover a commercially necessary process, but process claims are usually harder to enforce against an independently developed manufacturing route than composition claims.
What licensing deals support revumenib?
Syndax has retained primary commercial responsibility for Revuforj in the United States. The company has used partnerships and licensing arrangements to support international development and commercialization strategy, including regional rights and collaboration structures disclosed in corporate filings.[7]
The commercial value of any international deal depends on:
- Upfront payment.
- Development and regulatory milestones.
- Sales milestones.
- Royalty rates.
- Territory retained by Syndax.
- Responsibility for clinical trials and manufacturing.
- Rights to future indications such as NPM1-mutated AML.
Partnership economics can reduce Syndax’s launch burden outside the United States but also limit retained revenue and control.
What litigation and regulatory risks affect Revuforj?
The primary regulatory risk is accelerated-approval dependence. Syndax must complete confirmatory work sufficient to verify clinical benefit. Failure to confirm benefit can lead to label modification or withdrawal under the FDA accelerated-approval framework.[1]
The main legal risks are:
- Paragraph IV patent challenges.
- Patent validity attacks based on obviousness or written description.
- Patent-enablement disputes.
- Method-of-use litigation.
- Hatch-Waxman litigation involving Orange Book patents.
- Contract disputes involving licensing or commercialization territories.
- Antitrust scrutiny of patent settlements.
The main clinical and labeling risks are differentiation syndrome, QT prolongation, drug interactions, and the need to define the most effective treatment combinations.
What is the revenue exposure and investment profile?
Revumenib is the dominant value driver for Syndax because the company lacks a comparable marketed product. The risk profile is therefore concentrated rather than diversified.
Bull-case drivers
- Strong uptake in academic and community leukemia centers.
- High treatment persistence in responding patients.
- Successful use before transplant.
- Positive confirmatory results.
- Approval in NPM1-mutated AML.
- Expansion into frontline AML or combination regimens.
- Favorable reimbursement and broad molecular-testing adoption.
Base-case drivers
- Continued use in relapsed/refractory KMT2A leukemia.
- Moderate patient identification.
- Limited but recurring revenue from transplant-eligible and transplant-ineligible patients.
- High ongoing clinical and commercial costs.
- Gradual revenue growth tied to additional indications.
Bear-case drivers
- Confirmatory-trial failure.
- Differentiation syndrome or QT-related prescribing limitations.
- Slow adoption of molecular testing.
- Inferior efficacy relative to competing menin inhibitors.
- Early patent challenge.
- High gross-to-net discounts.
- Limited duration of treatment because patients proceed rapidly to transplant or discontinue for toxicity.
Revuforj can become a meaningful specialty-oncology product if Syndax expands beyond KMT2A-rearranged relapse. The initial indication alone is unlikely to support the same revenue scale as a broad AML therapy.
Key Takeaways
- Revumenib citrate is marketed as Revuforj and was FDA-approved in November 2024.
- It is the first approved menin inhibitor and targets KMT2A-translocated acute leukemia.
- The initial market is small but medically urgent and commercially valuable because treatment options are limited.
- Syndax’s largest growth opportunity is expansion into NPM1-mutated AML and earlier treatment lines.
- Patent protection is expected to include composition, formulation, and method-of-use claims, but exact loss-of-exclusivity dates depend on Orange Book listings and patent-term calculations.
- No established generic competitor was present at the initial launch.
- Ziftomenib is the most direct clinical competitor, particularly in NPM1-mutated AML.
- Revumenib is the central financial asset for Syndax, but launch profitability depends on market expansion and postapproval clinical execution.
- The principal risks are accelerated-approval obligations, safety monitoring, narrow initial eligibility, competitive menin inhibitors, and future Paragraph IV litigation.
Frequently Asked Questions
Is revumenib citrate the same as Revuforj?
Yes. Revuforj is the marketed product containing revumenib citrate.
Is revumenib a chemotherapy drug?
No. Revumenib is an oral targeted menin inhibitor. It may be used alone or in combination with other leukemia treatments under clinical protocols.
Is Revuforj approved for NPM1-mutated AML?
The initial FDA approval was for relapsed or refractory acute leukemia with a KMT2A translocation. NPM1-mutated AML is a major clinical-development and market-expansion opportunity rather than the basis of the initial approval.
Can a generic manufacturer launch revumenib after five years?
Not necessarily. Five-year new chemical entity exclusivity is only one regulatory barrier. Patent protection, orphan exclusivity, patent litigation, and any pediatric exclusivity can delay or restrict market entry.
Why is molecular testing important for revumenib sales?
Revumenib is indicated for a genetically defined leukemia population. Testing for KMT2A rearrangements identifies eligible patients and directly determines the size of the treatable market.
References
- U.S. Food and Drug Administration. (2024). FDA grants accelerated approval to revumenib for relapsed or refractory acute leukemia with a KMT2A translocation.
- U.S. Food and Drug Administration. (2024). Revuforj (revumenib) prescribing information.
- National Cancer Institute. (2024). Acute myeloid leukemia and mixed-phenotype acute leukemia treatment information.
- Syndax Pharmaceuticals, Inc. (2024). AUGMENT-101 clinical development materials and corporate disclosures.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity provisions.
- Syndax Pharmaceuticals, Inc. (2024). Annual report and intellectual-property disclosures.
